PV-10: Phase I expanded

Provectus expanded an open-label, dose-escalation, U.S. Phase I trial evaluating single injections of 0.25 and 0.5 mL PV-10 per mL lesion volume in up to 6 patients with cancer metastasized to the liver or with recurrent HCC to include 2 additional cohorts. One cohort will enroll up to 24 patients to evaluate the high dose, and the second, dose-escalation cohort will enroll up to 12 patients already receiving sorafenib for at least 4 weeks to evaluate both doses plus sorafenib. ...